A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

We previously reported that the combination of two safe proteostasis regulators, cysteamine and epigallocatechin gallate (EGCG), can be used to improve deficient expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in patients homozygous for the CFTR Phe508del mutation. Here...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Death Differ
Auteurs principaux: Tosco, A, De Gregorio, F, Esposito, S, De Stefano, D, Sana, I, Ferrari, E, Sepe, A, Salvadori, L, Buonpensiero, P, Di Pasqua, A, Grassia, R, Leone, C A, Guido, S, De Rosa, G, Lusa, S, Bona, G, Stoll, G, Maiuri, M C, Mehta, A, Kroemer, G, Maiuri, L, Raia, V
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2016
Sujets:
Original Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4947669/
https://ncbi.nlm.nih.gov/pubmed/27035618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2016.22
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires